Takeda Wins U.S. Approval Of Velcade Cancer Drug In Injectable Form
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical said it has received U.S. FDA approval to market a new version of Velcade (bortezomib) for treating cancer.